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Abstract
Until recently, relaxin has been known as a hormone that pertained to the female reproductive system. Its ability to remodel the 
extracellular matrix is responsible for its known reproductive effects. Current research has indicated that it may be useful as a 
drug to combat fibrosis. Relaxin has been proposed as an antifibrotic drug to target a variety of organs, including the skin, lung, 
kidney, liver, and heart. Studies done using the relaxin null knockout mouse have given scientists insight into the workings of this 
hormone. Human studies have also been done to test the efficacy of relaxin in its reversal of fibrosis. With more research, perhaps 
relaxin can be used as a drug in the future. 
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Introduction
Fibrosis is a hardening or scarring of tissue that results from 
the repair of injuries in the body.  It is estimated that 45-50% 
of deaths in the Western world are caused wholly or in part 
by fibrosis in various organs in the body. Currently, there is no 
available cure for damage caused by fibrosis (Summers, 2016).
Relaxin is a peptide hormone usually associated with the re-
productive system. Relaxin has been found to be pleiotropic, 
meaning that it is active in many varying roles in the body. It is 
produced in both pregnant and non-pregnant females as well 
as in males (Pallardy, 2016). It appears that relaxin can be ma-
nipulated to target injured organs in order to reverse fibrosis 
and prevent its further progression. There have been studies 
conducted that point to relaxin as a possible cure for fibrosis 
in various organs, including the skin, lung, kidney and heart (Tan, 
et. al. 2016). Fibrosis is a part of the pathology of many different 
human diseases and thus is said to account for 45-50% of deaths 
in the western world (Summers, 2016). 
Methods
Information in this paper is based primarily on research ac-
cessed through the Touro Library Databases. The peer reviewed, 
scholarly journal articles were retrieved through the Proquest 
or Pubmed databases. 
Fibrosis and its Causes
Fibrosis is an exaggeration of the scarring and hardening of tis-
sue usually caused by the body’s normal response to injury. It is 
characterized by a build-up of extracellular matrix (ECM) com-
ponents, or scar tissue, in place of normal tissue. Particularly, 
there is a buildup of fibrillar collagens, such as types I and III. 
Fibrogenesis is the body’s mechanism of healing and repairing 
wounds. What occurs in fibrogenesis is that myofibroblasts rush 
to the site of the injury and release cytokines. This causes fibro-
blasts to proliferate and build up the ECM producing fibrillar 
collagen creating a scar in place of the damaged tissue (Baum, et. 
al. 2011). Excessive build-up of connective tissue can be harm-
ful to underlying tissue and organs. This is because the ECM is 
the framework for the cells and extracellular structures in the 
body. Therefore, if the normal form of the ECM is disrupted, the 
tissue in which it is present will not continue to function as it 
should (Bathgate, et. al. 2003). Fibrosis is often caused by chronic 
inflammatory reactions that can be a result of various stimuli 
among which are persistent bacterial and viral infections, auto-
immune and allergic reactions, and tissue injury (Wynn, 2008).
The body has a system that works to clear accumulated ex-
tracellular matrix materials. Matrix Metalloproteinases (MMP’s) 
are a group of enzymes that break down extracellular matrix 
proteins, such as collagen. Part of the body’s normal way of 
repairing itself after tissue injury is to inhibit the production 
of these enzymes and to increase the secretion of Matrix 
Metalloproteinase Inhibitors (MMPIs), and more specifically, 
Tissue Inhibitors of Metalloproteinases (TIMPs).  Thus, scar tis-
sue replaces the injured tissue, and the body can heal itself. This 
too is favorable in a normal situation, but if this process contin-
ues unceasingly, it can result in disruption of normal organ func-
tion as the matrix builds up without anything present to break 
it down. An imbalance between collagen degrading enzymes will 
also cause fibrosis (Bennett, et. al. 2009). 
What is Relaxin?
Relaxin was first discovered in 1926 by Frederick Hisaw as a 
hormone present in pregnant guinea pigs. The function of re-
laxin observed at the time, was that it relaxed the pelvic liga-
ments and the cervix of the uterus to make it possible to carry 
the fetus and to prepare the area for parturition. Later, it was 
discovered that it was through collagen remodeling that relax-
in was able to play this important role in pregnancy and birth 
(Pallardy, 2016). Upon closer inspection of the relaxed ligaments 
it was seen that the collagen was remodeled from dense bun-
dles to looser, less structured fibers (Bennett, et. al. 2009).
Relaxin is produced by various structures in the female’s re-
productive tract including the placenta, corpus luteum and uter-
us, though this varies by species. During the first trimester of 
pregnancy, relaxin rises from practically undetectable levels to 
1ng/mL and then slowly wanes as delivery draws near. Relaxin is 
also present in non-pregnant human females and males (Pallardy, 
2016). In males, relaxin is produced by the prostate gland and 
can be found in the seminal fluid, though it is not usually detect-
ed in circulation (Bennet, 2009).
Relaxin is a peptide hormone whose two-chain structure is 
similar to that of insulin. In humans and higher primates, three 
genes for relaxin have been discovered, which include encod-
ing proteins known as H1, H2 and H3 relaxin. In rodents, only 
two relaxin genes have been discovered: relaxin-1 and relaxin-3, 
which are equivalent to the H2 and H3 in humans, respectively. 
The H3 relaxin gene was discovered in 2002 and is known to 
act mainly in the brain. H2 relaxin in humans- the product of the 
RLN2 gene, and relaxin-1 in rodents- the product of the RLN1 
gene, are the major circulating forms of relaxin and are the ones 
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that are thought to have an effect on fibrosis (reference to re-
laxin for the duration of the paper will refer to these forms of 
relaxin) (Samuel, et. al. 2007).
There has been a lot of research in the past few years that has 
tried to find more uses for relaxin in the body. There have been 
identified relaxin-binding sites in various places in the body in 
both males in females, including in the heart and brain. This sug-
gests that relaxin may also influence nonreproductive areas of 
the body and leads scientists to do further research into these 
possible uses (Samuel, et. al. 2016). 
Knockout Mouse Studies
To aid scientists in the understanding of relaxin, a relaxin-null 
nockout mouse was created by The Howard Florey Institute 
in Melbourne, Australia. A knockout mouse is a mouse that 
was genetically modified in order to remove or “knockout” a 
specific gene. Using such a mouse helps give scientists insight 
into the biology of a particular gene (Austin, et. al. 2004). The 
mouse established to research relaxin is the Rln1-KO mouse, 
meaning that the Rln1 gene, that codes for the major circulat-
ing form of relaxin in animals, was removed. However, the Rln3 
gene was not removed. Monitoring the development of these 
mice showed that the reproductive organs, in both males and fe-
males, were underdeveloped. In pregnant females, the mammary 
glands, nipples, and pubic symphysis were underdeveloped, and 
lactation was prevented. In the male mice, the testis, epididymis 
and prostate did not mature properly. Later, it was discovered 
that abnormal development in knock-out mice was due to ex-
cess collagen. In addition to this, as the mice aged, there was a 
buildup of interstitial collagen in the heart, lung, kidney, and skin. 
This eventually caused malfunction in these organs, appearing 
more prominently in the male mice. 
Scientists then administered recombinant human (H2) relaxin 
to the knockout mice and saw that it was helpful in reversing the 
fibrosis and restoring organ function. The relaxin was helpful in 
both early and late stages of the fibrosis, but worked to different 
extents depending on the organ. These findings point to a use of 
relaxin as a drug to reverse and prevent fibrosis in human patho-
logical situations (Bathgate, et. al. 2003 and Samuel, et. al. 2005b). 
In 2009 a study was done on relaxin null knockout mice to 
test the efficacy of using recombinant relaxin as a treatment 
for the fibrosis that developed in them. The study also aimed to 
test if it was significant when in the progression of the fibrosis 
the relaxin was administered. There were two groups of mice, in 
one group, relaxin was given to 9 month-old mice, during early 
stages of fibrosis. The other group was given relaxin when their 
fibrosis was more progressed, at 12 months of age. There was 
less fibrosis in the 9-month group, and no difference in the 12-
month group when compared to the untreated controls. This 
points to the fact that administered relaxin will be more effec-
tive in earlier stages of fibrosis (Giannakis, et. al. 2009).
Relaxin null knockout mice were used to test the effects of 
relaxin on scleroderma, a form of dermal fibrosis. It is a con-
nective tissue disease that causes fibrosis or various internal 
organs in addition to skin thickening. Untreated, scleroderma 
can cause irreversible damage. The study indicated that relaxin 
is more effective in treating dermal fibrosis in its early stages.  
(Samuel, et. al. 2005a).
How does Relaxin Help Reverse Fibrosis?
Relaxin binds with its endogenous receptor, relaxin family 
peptide receptor 1 (RXFP1), which is also known as LGR7. 
This inhibits the actions of major profibrotic factors such as 
transforming growth factor beta 1 (TGFb1), and angiotensin II 
in several organs. As a result of this, there will be a decreased 
expression of types I, III, and V collagens, interstitial collagens 
and type IV basement membrane collagen. There will also be 
an increase in the breakdown of collagen via the activation of 
MMP’s and an inhibition of the TIMPs (Samuel, et. al. 2016, fig 1)
Mechanisms
The mechanisms involved in the antifibrotic effects of relaxin 
are not currently well known by the scientific community. The 
primary receptor for relaxin is LGR7, or RXFP1, and was only 
recently discovered in 2002. Before this was known, the LGR7 
and LGR8 relaxin receptors were known as orphan G-protein 
receptors.  (Bennet, 2009). It is interesting to note that these re-
ceptors exist in organs outside the reproductive tract, pointing 
to the fact that relaxin has other functions than it was histori-
cally thought. Perhaps as the understanding of the pathway used 
by relaxin is enhanced, we will better be able to use relaxin as a 
drug for the treatment of fibrosis (Samuel, et. al. 2005a). 
Discussion: Clinical Trial for Relaxin
In the 1950’s, there was the emergence of the idea that relaxin 
could be used to treat fibrosis, and it was clinically tested then 
and again in the 1990’s. These studies failed to reach the lev-
els of effectiveness that were required for it to pass as a drug, 
but shed a lot of light onto the antifibrotic actions of relaxin 
(Samuel, et. al. 2005a).
A randomized, double-blind, placebo-controlled study was 
conducted using recombinant human relaxin in the treatment 
of systemic sclerosis. This was a phase III trial for testing relaxin 
as a possible drug to reverse fibrosis. Systemic sclerosis, also 
called systemic scleroderma, is a disease in which there is a 
buildup of collagen in various organs in the body. This is an ideal 
disease with which to test for the efficacy of relaxin, as the 
hallmark of this disease is ongoing fibrosis. The patients were 
divided into 2 random groups, one of which was given the actual 
drug, and the other group was given a placebo. In addition to 
this, neither those being treated, nor the researchers admin-
istering the medication knew who belonged to which group. 
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There was not a significant difference in the levels of fibrosis 
between the two groups. In addition, it seems that there were 
negative side effects to those that were administered the relaxin 
drug. The forced vital capacity in those patients given relaxin 
was decreased, and there were adverse renal effects primarily 
after they stopped giving them the relaxin. The study concluded 
that if relaxin is ever to be used in the reversal of fibrosis, there 
must be intensive monitoring of blood pressure and of renal 
function (Khanna, et. al. 2009). 
One proposed reason for why relaxin was not effective in this 
study was because the degree of scleroderma in the patients in 
this trial was quite advanced. In the relaxin-null mouse model it 
was also seen that relaxin was less effective in more advanced 
stages of fibrosis (Bennet, 2009).  Although this study is less opti-
mistic about the use of relaxin as a drug in the near future, it may 
be possible that as research continues, and we learn more about 
relaxin and how it works in the body, it will seem more plausible. 
Other Human Relaxin Studies
There was a study done to test the safety of administering re-
combinant human relaxin to people. The scleroderma patients 
were administered 200mcg/kg/day for 28 days. This is approx-
imately 50 times the relaxin present in a normal pregnant 
woman. The relaxin was unhelpful in reducing the fibrosis, but 
it was concluded that in these doses relaxin was safe and well 
tolerated. Some adverse side effects included; Development of 
a rash and pain at the site of infusion, minor bleeding in some 
cases, and decreased concentration of blood hemoglobin 
(Seibold, et. al. 1998).
It appears that the body itself uses relaxin as a mechanism to 
combat fibrosis. This was shown in a study of 50 patients with 
systemic sclerosis, an autoimmune disorder that causes fibrosis 
of the skin and internal organs, and 50 healthy patients in which 
normal relaxin levels were measured and the results were sta-
tistically analyzed. In the diseased patients, the measured levels 
of relaxin in the bloodstream was significantly higher than in the 
healthy subjects. It was hypothesized that this was the body’s 
response and effort to reverse the fibrosis (Giordano, et. al. 
2005). Thus, using relaxin as a drug for fibrotic patients is in 
accordance with the way nature would tackle the problem, and 
therefore worth further research. 
Pulmonary Fibrosis 
IPF or Idiopathic Pulmonary Fibrosis, is a lung disease in which 
there is fibrosis of the lungs for an unknown reason. It was 
found that the gene expression of the main relaxin receptor, 
RXFP1, is 2.9-fold less in lung samples taken from patients with 
IPF compared with lungs of normal control subjects. There 
was also a study done in an in vitro model, in which IPF fibro-
blasts were grown in media that was treated with transform-
ing growth factor TGFb1. It was found that the expression of 
the RXFP1 protein was decreased in immunoblots. It was thus 
hypothesized that relaxin treatments will not be too effective 
in patients with IPF. The authors also speculate that the loss 
of RXFP1 expression is a common factor in fibrotic diseases 
and therefore may have been part of the reason that the clin-
ical trials to treat scleroderma with relaxin failed (Tan, et. al. 
2016). Royce et. al. point out that these findings are surprising 
because relaxin has proved to be effective in reducing fibrosis in 
many human fibroblast culture models in which TGFb1 is used 
to stimulate collagen synthesis. They argue that the function-
al activity of the relaxin receptor cannot be determined using 
gene expression studies alone and point out that there may 
have been other factors involved that caused these results. 
Therefore, they conclude, more research must be done before 
relaxin-based therapies for fibrosis can be either ruled out or 
implemented clinically (Royce, at al, 2016).
Hepatic fibrosis
Fibrosis of the liver, like forms of fibrosis in other organs, is cat-
egorized by increased collagen deposition and decreased ECM 




Ang II and TGF-B1
Collagen
Deposition
MMP Expression TIMP Activity
Increased ECM/Collagen Degradation
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Fig.1 Mechanism for relaxin’s role in inhibiting fibrogenesis. (Modified 
from Samuel, et. al.2016.)
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vivo, scientists established fibrosis in mice using carbon tetra-
chloride. The mice were administered the carbon tetrachloride 
for 4 weeks, followed by 4 weeks of administration of relaxin in 
addition to carbon tetrachloride. Relaxin decreased the hepatic 
collagen expression, increased the expression of the MMPs, and 
decreased the TIMPs. This suggests that relaxin might be a possi-
ble treatment for established hepatic fibrosis (Bennet, et. al. 2014).
The common endpoint of many liver diseases caused by 
chronic liver injury is fibrosis. The major profibrogenic cell type 
that is activated in cases of chronic liver injury is the hepatic 
stellate cell-myofibroblast (HSC-MF). This cell produces scar tis-
sue and contributes to portal hypertension (PHT) by increasing 
the resistance within the hepatic vascular system. It was seen 
in past studies that the expression on RXFP1 was increased in 
human and rat HSC-MFs and in various studies on parts of the 
liver that were affected by fibrosis. In the model of rat fibrosis 
it was seen that the administering relaxin helped to reduce the 
fibrogenesis and reduce the PHT (McBride, et. al. 2017).
Relaxin has a short in vivo half-life. This is an obstacle to using 
it as a drug for treatment, especially in models of disease that re-
quire long-term administration of the drug, such as liver disease. 
In an effort to find a new drug to combat liver fibrosis, there 
was an attempt to find small molecules that are similar to relax-
in and that will act as agonists for the RXFP1 receptor. There are 
currently high throughput screening (HTS) technologies which 
allow scientists to explore vast libraries of compounds in a quick 
and efficient manner. This helps to identify molecules that can be 
used as starting points for creating new drugs. One compound, 
ML290, was found to be most promising. It binds with RXFP1 
and was therefore tested extensively. Although ML290 did ex-
hibit some relaxin-like activity, there were many differences in 
the way it bound to RXFP1 and its actions. Its effectiveness in 
combating liver fibrosis has not yet been tested and for now it 
does not seem that it will be a feasible replacement compound 
for the treatment of fibrosis. Also, being as the actions of RXFP1 
differ in various organs of the body, and are not well understood 
in general, more research must be done before such a drug can 
be produced (McBride, et. al. 2017). 
Cardiac Fibrosis
Fibrosis is a hallmark of hypertensive cardiac disease. The ECM 
has a great impact on the function of the heart, including regu-
lating ventricular diastolic and systolic function. It also provides 
the framework for the cardiomyocytes and coronary vessels. 
There are many cardiac pathologies that result in fibrosis. 
Among these are ischaemic injury, myocardial infarction, hy-
pertension, and many others. This results in a vicious cycle, as 
the accumulation of extracellular matrix via fibrosis leads to an 
increase in the amount of those negative cardiac events, which 
can in turn lead to more fibrosis. It was shown in relaxin knock-
out mouse studies that relaxin deficient mice have an elevated 
collagen content in their cardiovascular system which leads to 
diastolic dysfunction of the left ventricle (LV). 
Spontaneously hypertensive rats (SHR), in which fibrosis was 
not induced by having a lack of relaxin, rather it was the natu-
ral result of hypertension, were studied. When the rats were 
administered relaxin over a 14 day period the initially elevated 
collagen levels in the LV were now reduced. Fibroblast prolifera-
tion was inhibited, and MMP-2 expression increased. This means 
that there was a decrease in collagen synthesis as well as an 
increase in its breakdown. The study concluded that relaxin is a 
potent drug that can be used to combat hypertensive diseases. 
In addition to this, relaxin was compared to other hypertensive 
drugs such as angiotensin converting enzyme inhibitors and al-
dosterone inhibitors. These drugs have many side effects and 
only begin to help after prolonged periods of treatment. Relaxin, 
on the other hand, managed to work at a much faster rate to 
reduce fibrosis and did not have any notable side effects in this 
study (Lekgabe, et. al. 2005).
Renal Fibrosis
Renal fibrosis is the accumulation of collagen in the kidney. 
Specifically, in the renal resistance vessels, glomeruli and inter-
stitial space. There is a very strong relation between cardiovas-
cular diseases and renal diseases, as both diseases include high 
blood pressure. The SHR were also used to study renal involve-
ment. The experimental rats exhibited renal as well as cardiac 
fibrosis. Administration of relaxin over a 14-day period showed 
to reduce the fibrosis in the kidney cortex, thus halting renal 
failure. (Lekgabe, et. al. 2005).
Another study treated rats with bromoethylamine, or BEA, 
which causes severe renal interstitial fibrosis, one week later, the 
rats were administered relaxin via an osmotic pump for a period 
of 28 days. The aim was to see whether the relaxin would inhibit 
the fibrosis that was caused by the BEA. The structure of the renal 
tubules had been affected by much collagen deposition in the rats 
treated with BEA alone. The rats treated with BEA in conjunction 
with relaxin exhibited  a 75% decrease in collagen deposition and 
tubular structure was almost completely maintained.  In addition 
to this, it was seen that renal function was largely restored in the 
relaxin-treated animals. The levels of creatinine clearance were 
75% of those of the control mice. It is thus hypothesized that 
the reduction of the fibrosis by relaxin is the cause for the resto-
ration of renal function (Garber, et. al. 2001).
Conclusion
Fibrosis accounts for nearly half the deaths in the western world 
and yet there are no known cures. Relaxin’s natural antifibrotic 
properties make it a viable candidate for the treatment of fibrosis. 
Although much research has already been done, relaxin must be 
proven to be both safe and effective before it can begin to be im-
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